• Revenue growth driven by sequencing activities and strategic investments in growth segments.
  • Positive outlook confirmed for 2021 supported by synergies following integration into the OncoDNA Group.

Regulatory News:

IntegraGen (FR0010908723 – ALINT –Eligible PEA PME), a company specializing in the decryption of the human genome, which performs interpretable genomic analyses for academic and private laboratories, today announced its financial results for the first half of 2020. The accounts were approved by the Board of Directors at a meeting held on 7 October 2021.

Primary indicators – IN THOUSANDS OF EUROS

 

H1 2021

 

H1 2020

 

Var. %

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales

 

5,014

 

4,706

 

+7%

EBITDA

 

-331

 

248

 

n.a.

EBIT

 

-447

 

132

 

n.a.

 

 

 

 

 

 

 

Cash

 

4,272

 

5,774

 

 

Bernard Courtieu, CEO of IntegraGen, said: “IntegraGen’s results for the first half of 2021 confirm the success of our growth strategy despite the continued major constraints associated with the Covid-19 pandemic. This performance confirms the soundness of our model of focusing on genomics and has been enabled by the trust and loyalty of our customers, as well as by the efforts and dedication of all IntegraGen employees.

The company’s EBITDA continues to evolve because of investment in personnel, particularly in the field of Quality Assurance and Quality Control. This investment will enable u to expand our offer to pharmaceutical and biotechnological customers leading to additional growth opportunities.

Lastly, the industrial and commercial merger with the Belgian company OncoDNA is in progress and the first synergies between the two have proven the value of the combination of the two companies which was finalized in 2020.”

FINANCIAL RESULTS

  • Income statement

In thousands of euros

 

H1 2021

 

H1 2020

 

 

 

 

Sales

 

5,014

 

4,706

Operating grants and other income

 

124

 

39

Total revenue

 

5,138

 

4,745

EBITDA

 

(331)

 

248

Depreciation and other provisions

 

(116)

 

(116)

EBIT

 

(447)

 

132

Financial results

 

(21)

 

3

Exceptional results

 

(3)

 

(166)

Taxes

 

59

 

47

Net result

 

(411)

 

17

Sales revenue for the first half 2021 was 5,014 K€, up 7% compared to 4,706 K€ during the same period in 2020. Excluding recharge of personnel costs to the parent company (172 K€), sales revenue amounted to 4,843 K€, an increase of 3%. These figures exclude diagnostic business associated revenue, the assets of which were sold at the start of 2020.

After taking into account transfers of charges and other items, operating income amounted to 5,139 K€ compared to 4,745 K€ in the first half of 2020.

Operating expenses amounted to 5,586 K€, up 21% compared to the first half of 2020. This increase can be explained by various factors including the increase of consumables cost, the recharge of personnel costs from the parent company (170 K€), and the increase in payroll costs as a result of hires made over the last twelve months. At the end of June 2021, the company had 56 employees compared to 47 a year earlier. This increase also illustrates the investments in Quality as part of effort to obtain certifications for our laboratory in the Évry.

EBITDA represented a loss of 331 K€ compared to a profit of 248 K€ in the first half 2020, mainly due to an increase in operating expenses.

After taking into account exceptional items, the net result was a loss of 411 K€ compared to a profit of 17 K€ during the first half last year.

  • Balance sheet

In thousands of euros

 

06/30/21

 

12/31/20

Fixed assets

 

780

 

874

Stock

 

348

 

238

Accounts receivables

 

2,409

 

2,141

Other receivables

 

174

 

254

Cash

 

4,272

 

5,124

Current assets

 

7,426

 

7,948

Translation difference

 

10

 

0

TOTAL ASSETS

 

8,217

 

8,822

 

 

 

 

In thousands of euros

 

06/30/21

 

12/31/20

Shareholders’ Equity

 

1,759

 

2,171

Provisions for risks and charges

 

10

 

53

Financial Debt

 

1,983

 

2,015

Accounts payables

 

2,984

 

2,778

Other payables

 

910

 

1,091

Translation difference

 

0

 

1

TOTAL LIABILITIES

 

8,217

 

8,822

The available cash IntegraGen had at the end of June 2021 was 4,272 K€ compared to 5,124 K€ at the end of December 2020. This change was due to the flow of current transactions, change in working capital requirements and investments in quality systems. This cash position includes a State Guaranteed Loan (PGE) of 1,800 K€ obtained last year in the context of the Covid-19 pandemic.

Business

  • Genomic Services The sales growth the company experienced resulted from an increase of sequencing business, in particular the activity related to outsourced platforms (+37%) and the SeqOIA platform (+25%). Services dedicated to research laboratories and teams in charge of clinical research were temporarily down (-16%) despite a record in orders booked.
  • Software As a reminder, the company markets interpretation software and consulting services to its customers. These sales are stable given the limited commercial development and the delay in projects in recent quarters due to Covid-19 pandemic.

Outlook

IntegraGen has succeeded in months to successfully maintain a high level of activity for the services dedicated to research as well as for the company’s sequencing platforms for clinical use. Orders booked as of June 30, 2021 are increased compared to the same period of 2020, enabling sustained growth in activities for the second half of the year. The integration into OncoDNA Group has also opened up commercial prospects for IntegraGen through the Group's subsidiaries and distributors, which will have an impact for the second half of 2021.

About IntegraGen

IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has approximately 50 employees and generated €9 million in revenue in 2020. Based in France, IntegraGen is also present in the United States and is part of the OncoDNA group which works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late-stage solid tumors and accelerate the development of new cancer drugs.

IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 – Mnemo: ALINT – Eligible PEA- PME).

For further information, connect with us on LinkedIn or Twitter.

IntegraGen Bernard COURTIEU CEO

Pierre FLAMANT CFO contact@integragen.com Tel: +33 (0)1 60 91 09 00

NewCap Investor and Media Relations Louis-Victor DELOUVRIER integragen@newcap.eu Tel: +33 (0)1 44 71 98 53

Integragen (EU:ALINT)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Integragen
Integragen (EU:ALINT)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Integragen